Wells Fargo Gives a Buy Rating to Tenet Healthcare (THC)

In a report released today, Stephen Baxter from Wells Fargo assigned a Buy rating to Tenet Healthcare, with a price target of $265.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Baxter is an analyst with an average return of -1.4% and a 42.59% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Elevance Health, Cencora, and Community Health.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenet Healthcare with a $263.23 average price target.

Based on Tenet Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and a net profit of $371 million. In comparison, last year the company earned a revenue of $5.07 billion and had a net profit of $318 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Last month, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.